- Conditions
- Major Depressive Disorder
- Interventions
- Assay-guided treatment (AGT), Treatment-as-usual (TAU)
- Genetic · Other
- Lead sponsor
- Genomind, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 161
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Gastrointestinal Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation, Breast Cancer
- Interventions
- Availability of clinical decision support based on pharmacogenomic results.
- Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Embolism and Thrombosis, Embolism, Vascular Diseases, Warfarin, Venous Thromboembolism, Thrombosis, Thromboembolism
- Interventions
- CYP 2C9 and VKORC1 Testing for Warfarin
- Other
- Lead sponsor
- Medco Health Solutions, Inc.
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 1,635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Franklin Lakes, New Jersey
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Interventions
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 280
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Interventions
- Not listed
- Lead sponsor
- Genelex Corporation
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- Genotype Guided PPI Dosing
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Breast Cancer
- Interventions
- Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment
- Drug · Procedure · Other + 1 more
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more
- Conditions
- Hypercholesterolemia
- Interventions
- Pharmacogenetic and polygenic risk testing, Active control
- Genetic · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Durham, North Carolina
- Conditions
- Perioperative/Postoperative Complications
- Interventions
- PGx Testing
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Major Depressive Disorder, PTSD
- Interventions
- Phlebotomy - Folate, Cheek Swab, Self-report surveys
- Genetic · Other
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Antidepressants Causing Adverse Effects in Therapeutic Use
- Interventions
- PGx test
- Diagnostic Test
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- sorafenib tosylate, everolimus, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Buffalo, New York
- Conditions
- Type 2 Diabetes
- Interventions
- Pioglitazone
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 35 Years to 64 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pharmacogenetics, Pharmacogenomic Drug Interaction
- Interventions
- Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Major Depressive Disorder
- Interventions
- Genecept Assay
- Device
- Lead sponsor
- Genomind, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Intellectual Disability, Mild, Intellectual Disability, Mild to Moderate, Developmental Disability
- Interventions
- Cheek swab for PGx testing, Medication safety review
- Other
- Lead sponsor
- GalenusRx, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Montverde, Florida • The Bronx, New York
- Conditions
- Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Medullary Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7, Thyroid Gland Oncocytic Carcinoma, Unresectable Thyroid Gland Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Pharmacogenomic Study, Sunitinib, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2024
- U.S. locations
- 17
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 13 more
- Conditions
- Major Depressive Disorder 1
- Interventions
- Pharmacogenetic testing
- Genetic
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Breast Neoplasms, Tamoxifen
- Interventions
- Poor Metabolism Status Follow Up Therapy Considerations, CYP2D6 Inhibiting Drugs
- Other
- Lead sponsor
- Medco Health Solutions, Inc.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Franklin Lakes, New Jersey
- Conditions
- Adverse Drug Event, Drug Drug Interaction, Pharmacogenomics, Elderly
- Interventions
- Pharmacogenomic Testing
- Other
- Lead sponsor
- Tabula Rasa HealthCare
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Depression
- Interventions
- Pharmacogenetic testing, Clinical decisions support
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 1,572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 14
- States / cities
- Wilmington, Delaware • Gainesville, Florida • Jacksonville, Florida + 6 more
- Conditions
- Acute Pain, Surgery
- Interventions
- NeuroIDgenetix Test Panel
- Genetic
- Lead sponsor
- AltheaDx
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Interventions
- Pharmacogenetic testing
- Genetic
- Lead sponsor
- Genelex Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Searcy, Arkansas
- Conditions
- Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
- Interventions
- Warfarin GenoSTAT Test
- Device
- Lead sponsor
- Iverson Genetic Diagnostics, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 3,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more